FDA Approves Lilly-Ingelheim Treatment
Lilly completed the CoLucid acquisition in March.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe U.S. Food and Drug Administration has approved a type 2 diabetes treatment from Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals Inc. Synjardy was also approved earlier this year by the European Medicines Agency.
Lilly says Synjardy is the third product containing the medicine epagliflozin to be approved by the FDA, after Jardiance and Glyxambi. The company says Synjardi helps control blood glucose in type 2 diabetes patients. The approval is based on results from multiple clinical trials.
The companies say Synjardy is the fifth medicine developed through the alliance to be approved by the FDA. Boehringer Ingelheim Chief Executive Officer Paul Fonteyne says the partnership has resulted in a "diverse portfolio of treatments that can help patients throughout their diabetes journey."
